Bodor Laboratories, Inc.

Bodor Laboratories Inc. Announces Leadership Evolution with Erik Bodor as CEO and Highlights Milestones in Sofpironium Bromide Development

Menu Home Research & Development Pipeline The Science Recent Publications Selected Patents Company About Who We Are Partners News Contact Us Bodor Laboratories Inc. Announces Leadership Evolution with Erik Bodor as CEO and Highlights Milestones in Sofpironium Bromide Development Miami, FL, April 3, 2024 – Bodor Laboratories Inc. (BLI), a leader in innovative pharmaceutical research […]

Bodor Laboratories Inc. Congratulates Kaken Pharmaceutical on Partnership with Dong Wha Pharmaceutical for Marketing Sofpironium Bromide in Korea

Menu Home Research & Development Pipeline The Science Recent Publications Selected Patents Company About Who We Are Partners News Contact Us Bodor Laboratories Inc. Congratulates Kaken Pharmaceutical on Partnership with Dong Wha Pharmaceutical for Marketing Sofpironium Bromide in Korea Miami, FL, June 23, 2023 – Bodor Laboratories Inc., a privately held pharmaceutical research and development […]

Identification of esterase involved in the metabolism of two corticosteroid soft drugs

Abstract The soft drug approach is successful in obtaining high local therapeutic efficacy without systemic adverse effects, because soft drugs are designed to be bioconverted to inactive form by hydrolytic enzymes in systemic circulation. However, there is little information about the exact nature of these metabolic enzymes. In this study, the human enzymes for biotransformation of soft drugs were […]

Potent analogues of etiprednol dicloacetate, a second generation of soft corticosteroids†

†This paper is dedicated to Prof. Yuichi Sugiyama, Head of the Sugiyama Laboratory at RIKEN Innovation Center (Yokohama, Japan), in recognition of his 70th birthday.   Abstract Objectives Loteprednol etabonate (LE) is the first, highly successful soft corticosteroid (SC) designed using the ‘inactive metabolite’ approach, starting with ∆1-cortienic acid (d-CA). The next generation of SCs […]